Sun Pharmaceutical Industries has reported results for third quarter ended December 31, 2020.
The company has reported 18.51% rise in its net profit of Rs 555.55 crore for the quarter under review as compared to net profit of Rs 468.76 crore for the same quarter in the previous year. Total income of the company increased by 12.55% at Rs 3409.00 crore for Q3FY21 as compared Rs 3028.91 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported 2- fold jump in its net profit after taxes, share of profit of associates and joint ventures and non-controlling interests at Rs 1852.48 crore for the quarter under review as compared to net profit at Rs 913.52 crore for the same quarter in the previous year. Total income of the company increased by 10.60% at Rs 9151.73 crore for Q3FY21 as compared Rs 8274.73 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1862.70 |
| Dr. Reddys Labs. | 1356.85 |
| Cipla | 1465.15 |
| Zydus Lifesciences | 1112.20 |
| Lupin | 2420.15 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: